New Zealand’s low excess mortality during the Omicron outbreak a 'remarkable success"

Publicly released:
Australia; New Zealand; International
Image by Maxime on UnSplash
Image by Maxime on UnSplash

Of four territories that transitioned from a “zero-COVID” policy to a “living-with-COVID” policy following the Omicron outbreak in 2022, New Zealand was the only one that maintained a low excess mortality of less than 10%. Authors of the study call this a “remarkable success” largely attributed to New Zealand’s “ultra-high” vaccination rates, especially among the elderly. Singapore, South Korea, and Australia saw a rise in excess mortality of 20-40% following the adoption of a "living-with-COVID" policy in the first half of 2022, while Hong Kong saw an average increase of 71.14% during this time, largely due to extremely low vaccination rates among the elderly population.

Media release

From:

Expert Reaction

These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.

Professor Michael Baker, Department of Public Health/ Te Tari Hauora Tūmatanui, University of Otago, Wellington

This international study conducted by authors from China and the United States provides further evidence that the Aotearoa New Zealand Covid-19 response has been highly effective at minimised deaths during the pandemic.  Unlike many previous studies, it focusses on the period when Covid-19 began circulating widely in this country – what these author call ‘Living with Covid’ (LWC) – which occurred here from February 2022 onwards.  It also uses percentage excess mortality (PEM) as its main outcome measure, which allows robust comparisons across countries that have quite different disease surveillance systems.

The analysis covered five jurisdictions – four of which used elimination strategies (New Zealand, Singapore, Australia, and Hong Kong SAR) and one which suppressed transmission to low levels (South Korea).  As is well known, these strategies were very effective at minimising Covid-19 deaths and resulted in low or even negative excess mortality during the first one to two years of the pandemic.

What this study adds is a comparative analysis of excess mortality after these jurisdictions transitioned to LWC which occurred when the Omicron variant resulted in widespread transmission.  It showed that New Zealand was the only jurisdiction to sustain low excess mortality during this period of high infection (defined as a PEM of under 10%).  The other countries had PEM ranging up to 71.14% in the case of Hong Kong for the first half of 2022, and 39.85% in Australia during that period.

These findings fit with other ongoing analyses showing that New Zealand is one of the only countries to have sustained net negative excess mortality for the duration of the pandemic (i.e. from January 2020 until March 2023).

The results of this study support New Zealand’s strong focus on reducing the health impact of Covid-19.  These measures include promoting vaccination, mandatory self-isolation of cases, mask mandates in health care and aged care settings, and free access to antivirals for vulnerable groups.  It is important that we don’t become complacent to the ongoing impact of Covid-19.  Despite a decline in case numbers, this virus is still on track to put more than 10,000 New Zealanders in hospital and cause more than 500 deaths this year, based on present rates.

Last updated:  21 Mar 2023 12:08pm
Contact information
Contact details are only visible to registered journalists.
Declared conflicts of interest None.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Frontiers, Web page Open access
Journal/
conference:
Frontiers in Public Health
Research:Paper
Organisation/s: The Hong Kong Polytechnic University, Icahn School of Medicine at Mount Sinai, The Hong Kong University of Science and Technology
Funder: This work was supported by PolyU Internal Funding (#P0030234) to YZh, and the start-up fund of Hong Kong University of Science and Technology (Guangzhou) (# G0101000092) to YZi.
Media Contact/s
Contact details are only visible to registered journalists.